Evidence map›Paper›PMID 42170268›Full record

ArticleTranslational lung cancer research2026

"Variant matters": the impact of ALK fusion subtypes on progression and response in non-small-cell lung cancer-data from clinical practice from Polish centers.

Kinga Winiarczyk, Katarzyna Seliga, Paweł Krawczyk, Aleksandra Nowak, Izabela Chmielewska, Andrzej Tysarowski, Małgorzata Szołkowska, Michał Gil, Dariusz M Kowalski, Janusz Milanowski and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kinga WiniarczykDepartment of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.ORCID https://orcid.org/0000-0003-3872-0620
Katarzyna SeligaDepartment of Genetic and Molecular Cancer Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Paweł KrawczykDepartament of Pneumonology, Oncology, and Allergology, Medical University of Lublin, Lublin, Poland.
Aleksandra NowakDepartment of Genetic and Molecular Cancer Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Izabela ChmielewskaDepartament of Pneumonology, Oncology, and Allergology, Medical University of Lublin, Lublin, Poland.
Andrzej TysarowskiDepartment of Genetic and Molecular Cancer Diagnostics, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Małgorzata SzołkowskaDepartment of Pathomorphology, Institute of Tuberculosis and Lung Diseases, Warsaw, Poland.
Michał GilDepartament of Pneumonology, Oncology, and Allergology, Medical University of Lublin, Lublin, Poland.
Dariusz M KowalskiDepartment of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Janusz MilanowskiDepartament of Pneumonology, Oncology, and Allergology, Medical University of Lublin, Lublin, Poland.
Maciej KrzakowskiDepartment of Lung Cancer and Thoracic Tumours, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: For patients with advanced non-small-cell lung cancer (NSCLC) who have anaplastic lymphoma kinase ( Methods: We conducted a retrospective analysis of 61 patients with lung adenocarcinoma with detected Results: On the 61 tumours analyzed, variant 1 was the most common in the study group (37.7% of patients), followed by variants 2 and 3, found with similar frequency in the study population (in 27.9% and 21.3% of patients, respectively). Disease stabilization occurred slightly more often in patients with variant 1, and progressive disease (PD) slightly more often in patients with variant 3 of the Conclusions: Our results highlight the high efficacy of ALKi in achieving disease control (DC) in patients with

Indexed as

ALK inhibitors (ALKi)Anaplastic lymphoma kinase-rearrangement non-small-cell lung cancer (ALK-rearrangement NSCLC)echinoderm microtubule-associated protein-like 4-ALK fusion variants (EML4-ALK fusion variants)

Identifiers

PMID42170268
PMCPMC13186680

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.